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Abstract
Background: This paper reviews the current evidence indicating that comorbid allergic rhinitis
may have clinically relevant effects on asthma.
Discussion: Allergic rhinitis is very common in patients with asthma, with a reported prevalence
of up to 100% in those with allergic asthma. While the temporal relation of allergic rhinitis and
asthma diagnoses can be variable, the diagnosis of allergic rhinitis often precedes that of asthma.
Rhinitis is an independent risk factor for the subsequent development of asthma in both atopic and
nonatopic individuals. Controlled studies have provided conflicting results regarding the benefits
for asthma symptoms of treating comorbid allergic rhinitis with intranasal corticosteroids. Effects
of other treatments for comorbid allergic rhinitis, including antihistamines, allergen
immunotherapy, systemic anti-IgE therapy, and antileukotriene agents, have been examined in a
limited number of studies; anti-IgE therapy and antileukotriene agents such as the leukotriene
receptor antagonists have benefits for treating both allergic rhinitis and asthma. Results of
observational studies indicate that treating comorbid allergic rhinitis results in a lowered risk of
asthma-related hospitalizations and emergency visits. Results of several retrospective database
studies in the United States and in Europe indicate that, for patients with asthma, the presence of
comorbid allergic rhinitis is associated with higher total annual medical costs, greater prescribing
frequency of asthma-related medications, as well as increased likelihood of asthma-related hospital
admissions and emergency visits. There is therefore evidence suggesting that comorbid allergic
rhinitis is a marker for more difficult to control asthma and worsened asthma outcomes.
Conclusion: These findings highlight the potential for improving asthma outcomes by following a
combined therapeutic approach to comorbid allergic rhinitis and asthma rather than targeting each
condition separately.
Background
Many patients with asthma, particularly those with aller-
gic asthma, also have allergic rhinitis (AR). The mucosa of
the upper and lower airways is continuous, and the type
of inflammation in AR and asthma is very similar, involv-
ing T helper type 2 cells, mast cells, and eosinophils, as
reviewed in the following paper in the present supple-
ment [1]. Allergic rhinitis is now subdivided into intermit-
tent AR (symptoms <4 days per week or for <4 weeks) and
persistent AR (symptoms >4 days per week or for >4
weeks), rather than the previous subdivisions of seasonal
and perennial AR, and is further characterized according
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to severity as mild or moderate/severe [2]. Treatment of
AR is based on the subdivision and the severity.
Current evidence indicates that comorbid AR may have
clinically relevant effects on asthma. The database of evi-
dence is still relatively small, and much of the data come
from observational studies. Moreover, the definitions of
AR and asthma differ among studies. Nonetheless, the
association between AR and asthma was sufficiently
apparent that, in 1999, a workshop was held at the World
Health Organization to develop evidence-based guide-
lines for managing rhinitis and to highlight the impact of
AR on asthma. This global program – entitled the Allergic
Rhinitis and its Impact on Asthma initiative – is ongoing,
in collaboration with the World Health Organization, to
translate evolving science into clinical recommendations
for managing and preventing rhinitis, to better assess the
interactions between rhinitis and asthma, to increase
awareness of rhinitis, and to make effective treatment of
rhinitis available worldwide [2].
This paper reviews the current evidence indicating that
comorbid AR may have clinically relevant effects on
asthma. Nonallergic asthma and rhinitis appear also to be
associated, although these disorders are less well under-
stood than their allergic counterparts [2]. The designation
of 'nonallergic' is applied when the allergy examination,
including history, skin-prick testing, and serum-specific
IgE measurements, is negative.
Asthma and allergic rhinitis often occur 
concomitantly
AR is very common in patients with asthma [2], with a
reported prevalence of up to 100% in those with allergic
asthma [3]. In a recent review examining prevalence stud-
ies of comorbid AR published from 1983 to 2004 [4], the
point prevalence of AR ranged from 24% to 94% and the
lifetime prevalence ranged from 50% to 100% among
adults with asthma in Europe and in the United States.
These findings have been corroborated in more recent
studies from Europe and from Japan [5,6].
The variability in the reported prevalence of comorbid AR
in the studies reviewed was attributable in part to differ-
ences in diagnostic criteria and study design [4]. Geo-
graphical differences may exist also: in the only study
from Asia meeting the criteria for the present review [7],
the prevalence of comorbid AR in people with asthma in
rural China was lower (6%). Among school-age children
surveyed in the International Study of Asthma and Allergy
in Children, there are striking variations in the prevalence
of asthma and allergic rhinoconjunctivitis symptoms
recorded among different centers worldwide; nonetheless,
significant correlations (r = 0.75, P < 0.0001) are noted
between the prevalence of asthma and allergic rhinocon-
junctivitis symptoms [8,9].
Several medical database studies have examined the asso-
ciation between AR and asthma [10-13]. In the Rochester,
Minnesota, USA study [10], AR was most common (59%
prevalence) among people whose asthma was diagnosed
before age 25, and AR was relatively uncommon (15%)
among those whose asthma was diagnosed after age 40
(9% of all subjects). The overall prevalence of docu-
mented AR in this study was 52% among the 1,245
patients with asthma. In the UK Medi-Plus general prac-
tice database studies [11,12], concomitant AR was docu-
mented in medical records of only 17% of 27,303 patients
aged 16–55 years with asthma and in 20% of 9,522 chil-
dren with asthma. Similarly, of 2,961 children in the
national database in Norway with at least one hospital
admission for asthma over a 2-year period, 27% had a
documented history of AR [13]. It is possible that the prev-
alence of comorbid AR among patients in these retrospec-
tive studies was underestimated because the diagnosis of
AR was restricted to that recorded in medical records.
Many people with AR self-manage the condition with
over-the-counter products, do not seek a physician's help,
or indeed do not recognize AR as a condition needing
treatment [5].
Conversely, asthma is often present in patients with AR.
Linneburg and coworkers [3] reported asthma in 25% of
patients with AR who were pollen-sensitive and in 50% of
those AR patients who were mite-sensitive or animal-sen-
sitive. Greisner and coworkers [14] report a history of
asthma among 21% of former college students with a
cumulative history of AR over 23 years of follow-up.
In the European Community Respiratory Health Survey,
an association between asthma and rhinitis was observed
even in nonatopic individuals [15]. This finding implies
that the relationship cannot be fully explained by shared
risk factors and supports the hypothesis that upper-airway
disorders may directly affect the lower airways.
Impact of allergic rhinitis on asthma
While the temporal relation of AR and asthma diagnoses
can be variable, the diagnosis of AR often precedes that of
asthma [14,16]. In fact, rhinitis is an independent risk fac-
tor, both in atopic and nonatopic individuals, for the sub-
sequent development of asthma [16-20].
Bronchial hyperresponsiveness is common in people with
AR, even if they have no asthma symptoms, and asympto-
matic airway hyperresponsiveness is associated with
increased risk for developing asthma [21,22]. In one
study, 40% of patients with AR showed hyperresponsive-
ness to methacholine challenge; those showing hyperre-BMC Pulmonary Medicine 2006, 6(Suppl 1):S4
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sponsiveness were more likely to develop asthma over the
following 4–5 years [23]. Moreover, among patients with
seasonal AR, response to a nonspecific bronchial provoca-
tion test increases during the pollen season [24]. Among
patients who had shown exacerbation of asthma symp-
toms in conjunction with the onset of seasonal AR, nasal
allergen challenge resulted in increased nonspecific bron-
chial responsiveness [25]. As further evidence of a patho-
physiological link between upper and lower airways,
segmental bronchial provocation in patients with AR but
no asthma results in allergic inflammatory changes in the
nose [26].
Comparisons of the clinical characteristics of asthma in
patients with and without AR are few [27,28]. One small
study found that patients with perennial AR are more at
risk of developing bronchial symptoms than healthy con-
trol subjects [29]. Asthma exacerbations frequently occur
coincident with the worsening of nasal symptoms [6]. In
another study, asthma severity among atopic asthmatic
patients was less in those with nasal symptoms than in
those without nasal symptoms, whereas asthma severity
among nonatopic asthmatic patients was greater in those
with nasal symptoms than in those without nasal symp-
toms [28]. Conversely, among patients with severe, corti-
costeroid-dependent asthma, sinonasal involvement is
almost universal [30].
Several retrospective cost-of-illness studies have explored
healthcare costs for patients with asthma who have
comorbid AR [10-13,31]. In two US studies, total annual
medical costs were appreciably higher for patients with
comorbid AR relative to those with only asthma and no
AR [10,31]. In addition, in one study the presence of AR
was associated with higher costs and greater prescribing
frequency of asthma-related medications [31]. In Roches-
ter, Minnesota, total costs were 46% higher overall with
comorbid AR; however, when age groups were examined
separately, significantly higher costs with comorbid AR
were not evident beyond age 25 [10]. Moreover, for
patients from 55 to 64 years old, annual medical costs
were significantly higher for those with only asthma.
In the UK Medi-Plus general practice database studies, the
presence of physician-recorded comorbid AR was associ-
ated with a 50% increase in rate of hospitalization for
asthma among adults and a 250% increase in rate of hos-
pitalization for asthma among children during a 12-
month follow-up period [11,12]. The number of asthma-
related visits to a general practitioner and the asthma drug
costs were also significantly higher among both adults
and children with documented comorbid rhinitis. Simi-
larly, for Norwegian children with asthma, the presence of
comorbid rhinitis was associated with increased likeli-
hood of asthma-related hospital readmissions and greater
total hospital days [13]. In a recent German study of
patients with moderate-to-severe asthma, the annual cost
of illness increased for both children and adults with the
severity of asthma and the presence of concomitant sea-
sonal AR [32].
In the controlled trial setting, a post-hoc analysis of the
Investigation of Montelukast as a Partner Agent for Com-
plementary Therapy trial indicates that, in addition to
greater use of healthcare resources, outcomes are worse for
patients with comorbid rhinitis and asthma [33,34]. This
trial compared the addition of montelukast therapy or sal-
meterol therapy over 12 months for 1,490 adults with
mild-to-moderate asthma not controlled by inhaled fluti-
casone alone [33]. Self-reported comorbid AR was present
in 60% of patients enrolled in this study; these patients
tended to be younger and to have less severe asthma than
those with asthma alone. Nonetheless, significantly more
patients with comorbid AR experienced emergency room
visits and asthma attacks; the frequencies of hospitaliza-
tions and unscheduled or specialist visits were greater
among those with concomitant AR but did not differ sig-
nificantly between the two groups (Figure 1) [34].
Treatment of allergic rhinitis: effect on asthma-
related outcomes
The evidence thus suggests that comorbid AR is a marker
for more difficult to control asthma and for worsened
asthma outcomes. This leads to the question of whether
treating comorbid AR would produce better asthma-
related outcomes in addition to the obvious benefits with
regard to rhinitic symptoms. There is presently a paucity
of data on this topic, and there is some inconsistency in
reported outcomes with different AR treatment strategies.
Two small studies in the 1980s showed benefits of intra-
nasal corticosteroids for asthma symptoms. In one study,
considerable reductions in seasonal asthma symptoms
were recorded among patients with concomitant AR who
were treated with intranasal beclomethasone or flu-
nisolide [35]. In the second study, cough and exercise-
induced asthma symptoms were reduced among children
with perennial AR treated with intranasal budesonide
[36].
More recent studies have produced conflicting results
regarding the effects of intranasal corticosteroids on the
lower airways of patients with AR. Some of these studies
have shown decreased bronchial hyperresponsiveness
after treatment with intranasal corticosteroids [37-40],
while other studies failed to show this [41-44]. One study
reported positive effects of intranasal corticosteroids on
symptoms of asthma but not on bronchial responsiveness
[45], while another study showed no improvement in
asthma symptoms but the effects on bronchial respon-BMC Pulmonary Medicine 2006, 6(Suppl 1):S4
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siveness were not measured [46]. It is important to note
that all but one of these studies [46] enrolled small num-
bers of patients. In addition, study designs and patient
characteristics, including age and the concomitant pres-
ence or absence of asthma, differed among the studies.
Moreover, compared with newer intranasal corticoster-
oids, some of the older intranasal corticosteroids have
higher oral and systemic bioavailability; this may account
for effects on lower airways in some studies.
Effects of other treatments for comorbid AR, including
antihistamines, allergen immunotherapy, systemic anti-
IgE therapy, and antileukotriene agents, have been exam-
ined in a limited number of studies. Systemic effects of
these treatments may play a role in effects on bronchial
hyperresponsiveness and asthma symptoms. While anti-
histamines are not considered effective for treating
asthma per se, results of some studies suggest that an oral
antihistamine given to patients with comorbid AR and
asthma can improve persistent asthma symptoms [47]
and nonspecific bronchial hyperresponsiveness [48], as
well as asthma symptoms during the pollen season [49].
Similarly, there is recent evidence that immunotherapy
may clinically benefit lower airway function in patients
with AR, although the results are not consistent and the
study designs vary. Specific immunotherapy is reported to
reduce bronchial hyperresponsiveness in patients with AR
in some studies [50,51] but not in others [52,53]. In
recent reports, treatment with allergen immunotherapy
reduced the development of asthma in children and
adults with AR [54,55]. Systemic anti-IgE therapy also
shows promise for treating patents with comorbid asthma
and AR, particularly those with disease at the moderate to
severe end of the spectrum. Anti-IgE therapy with omali-
zumab improves symptoms, improves quality of life and
reduces asthma exacerbations in patients with concomi-
tant asthma and persistent AR [56].
Antileukotriene agents such as the leukotriene receptor
antagonists have benefits for treating both AR and
asthma. Philip and coworkers [57] report that montelu-
kast therapy improved asthma outcomes as well as pro-
viding significant relief from symptoms of seasonal AR in
a multicenter study of 831 adult patients with seasonal
Asthma-related resource use and asthma attacks according to the presence of concomitant allergic rhinitis Figure 1
Asthma-related resource use and asthma attacks according to the presence of concomitant allergic rhinitis. In a post-hoc anal-
ysis of the Investigation of Montelukast as a Partner Agent for Complementary Therapy trial, rates of asthma attacks and emer-
gency room visits were significantly higher among patients with comorbid asthma and allergic rhinitis (AR). Adapted with 
permission from Bousquet and coworkers [34].
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allergen sensitivity, with active symptoms of seasonal AR,
and with active asthma. Moreover, in a post-hoc analysis
of a randomized controlled trial comparing the addition
of montelukast with doubling the dose of inhaled corti-
costeroid for patients whose asthma was uncontrolled on
the standard dose of inhaled corticosteroid [58], out-
comes were superior for the 216 patients with comorbid
AR given montelukast than for the 184 patients with
comorbid AR given a doubled dose of inhaled corticoster-
oid; this finding implies an additional benefit to asthma
control from a systemic agent able to treat AR as well as
asthma [59]. By contrast, the results of adding montelu-
kast versus doubling inhaled corticosteroid were not dif-
ferent for the 497 patients with asthma alone [59].
In another recent study, Ragab and coworkers [60] report
improved asthma symptoms and asthma control correlat-
ing with improved upper airway symptoms after either
surgical or medical treatment of chronic rhinosinusitis for
patients with comorbid asthma. Significant improve-
ments in overall asthma control after either type of treat-
ment modality were recorded; however, improvements
were better maintained after medical therapy of rhinosi-
nusitis, which consisted of a 12-week course of oral eryth-
romycin, alkaline nasal douches, and intranasal
corticosteroids.
Recently published observational data also support the
concept that asthma outcomes are better, for both chil-
dren and adults, when comorbid AR is treated [61-63].
Crystal-Peters and coworkers [61] evaluated data for
almost 5,000 US patients aged 12–60 years with comor-
bid AR and asthma. They found for the three-quarters of
patients who were receiving treatment for AR that the risk
of an asthma-related event (hospitalization or Emergency
Department visits) was one-half that for patients not
receiving treatment for AR. Similarly, in an Australian
managed care population of 14,000 patients older than 5
years of age with asthma, treatment of nasal conditions
with intranasal corticosteroids substantially reduced the
risk of an Emergency Department visit for asthma [62],
although the methods of this study have been criticized as
allowing an immortal time bias to potentially act as a con-
founding factor [64].
Corren and coworkers [63] conducted a nested case–con-
trol study of a US managed care population of patients
aged 6 years and older. For those with concomitant
asthma and AR, treatment with either nasal corticoster-
oids or second-generation antihistamines was associated
with a significant reduction in risk of hospitalization for
asthma. Patients receiving nasal corticosteroids also had a
significantly lowered risk of asthma-related Emergency
Room treatment [63].
Conclusions and remaining questions
In summary, asthma and AR frequently occur concomi-
tantly. The presence of AR often precedes the develop-
ment of asthma and is a known risk factor for asthma.
There is evidence that having comorbid AR is a marker for
the presence of more difficult to control asthma and there-
fore greater use of resources for asthma. There are also
strong indications from observational data that treating
comorbid AR may result in better asthma outcomes.
Several questions remain to be answered by future studies.
Is AR being diagnosed properly in patients with asthma, as
recommended in the Allergic Rhinitis and its Impact on
Asthma guidelines? When AR is diagnosed, are patients
being treated in the best possible way? Indeed, what is the
best way of treating AR when comorbidity exists, with a
particular focus on the asthma outcomes?
At present, treatment typically follows a two-compart-
ment model whereby asthma and rhinitis are each treated
separately and often locally, or topically; treatment is
administered seasonally for people with seasonal rhinitis.
Asthma outcomes might improve for patients with
comorbid AR and asthma if treatment was instead long
term and followed a combined therapeutic approach for
the two conditions.
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